
Immutep Ltd (IMMP) Stock Forecast & Price Target
Immutep Ltd (IMMP) Analyst Ratings
Bulls say
Immutep Ltd is advancing its product candidate, eftilagimod alfa (efti), through a registrational Phase three clinical trial for first-line non-small cell lung cancer, which has shown promising efficacy by increasing the objective response rate (ORR) by 22.2% in patients with low tumor proportion scores. The company's robust patent portfolio and the ease of combining efti with existing therapies create significant opportunities for expanding its product offerings and strengthening its market position. With a diversified pipeline addressing various cancers and autoimmune diseases, Immutep's strategic development efforts potentially enhance its long-term financial prospects.
Bears say
Immutep's outlook is negatively impacted by the underwhelming clinical results from its lead product candidate, eftilagimod alfa (efti), which has led to a reduced probability of success in treating non-small cell lung cancer ( NSCLC) to just 30%. The overall efficacy results from the company's INSIGHT-003 trial are expected to be poorer than historical benchmarks, as the study includes a higher proportion of patients with low tumor mutational burden (TPS<1%), likely driving down efficacy outcomes. Moreover, the mixed results of LAG-3 antagonists in lung cancer and their perception as non-practice changing add to investor concerns regarding the future viability of Immutep's product portfolio.
This aggregate rating is based on analysts' research of Immutep Ltd and is not a guaranteed prediction by Public.com or investment advice.
Immutep Ltd (IMMP) Analyst Forecast & Price Prediction
Start investing in Immutep Ltd (IMMP)
Order type
Buy in
Order amount
Est. shares
0 shares